Psybio Therapeutics Corp Stock Probability of Future Pink Sheet Price Finishing Over 0.0193
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio |
PsyBio Therapeutics Target Price Odds to finish over 0.0193
The tendency of PsyBio Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 0.02 or more in 90 days |
| 0.0001 | 90 days | 0.02 | near 1 |
Based on a normal probability distribution, the odds of PsyBio Therapeutics to move over $ 0.02 or more in 90 days from now is near 1 (This PsyBio Therapeutics Corp probability density function shows the probability of PsyBio Pink Sheet to fall within a particular range of prices over 90 days) . Probability of PsyBio Therapeutics Corp price to stay between its current price of $ 0.0001 and $ 0.02 at the end of the 90-day period is about 68.02 .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 95.0 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PsyBio Therapeutics will likely underperform. In addition to that PsyBio Therapeutics Corp has an alpha of 303.1458, implying that it can generate a 303.15 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). PsyBio Therapeutics Price Density |
| Price |
Predictive Modules for PsyBio Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PsyBio Therapeutics Corp. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.PsyBio Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. PsyBio Therapeutics is not an exception. The market had few large corrections towards the PsyBio Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PsyBio Therapeutics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PsyBio Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 303.15 | |
β | Beta against Dow Jones | 95.00 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.12 |
PsyBio Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PsyBio Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PsyBio Therapeutics Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Aileron Therapeutics CEO James Brian Windsor buys 897 in stock |
PsyBio Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PsyBio Pink Sheet often depends not only on the future outlook of the current and potential PsyBio Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PsyBio Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 113 M | |
| Shares Float | 65 M |
PsyBio Therapeutics Technical Analysis
PsyBio Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. PsyBio Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PsyBio Therapeutics Corp. In general, you should focus on analyzing PsyBio Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
PsyBio Therapeutics Predictive Forecast Models
PsyBio Therapeutics' time-series forecasting models is one of many PsyBio Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PsyBio Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about PsyBio Therapeutics Corp
Checking the ongoing alerts about PsyBio Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PsyBio Therapeutics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Aileron Therapeutics CEO James Brian Windsor buys 897 in stock |
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.